Brian Hansen - Tandem Diabetes Chief Commercial Officer, Executive Vice President
| TNDM Stock | USD 20.65 0.03 0.15% |
President
Mr. Brian B. Hansen is the Chief Commercial Officer, Executive Vice President of Tandem Diabetes Care Inc. Mr. Hansen has served as our Executive Vice President and Chief Commercial Officer since February 2016. Prior to joining our Company, Mr. Hansen served from September 2014 as Chief Commercial Officer of Adaptive Biotechnologies Corporationration From May 2013 to September 2014, Mr. Hansen served as Head of Commercial, Sales and Marketing, of Genoptix, a Novartis Company. From December 2005 to February 2013, he served in various roles of increasing responsibility at GenProbe, Inc., a medical diagnostics company, most recently serving as Senior Vice President, Global Sales and Services from January 2012 to February 2013 since 2016.
| Age | 56 |
| Tenure | 9 years |
| Professional Marks | MBA |
| Phone | 858 366 6900 |
| Web | https://www.tandemdiabetes.com |
Brian Hansen Latest Insider Activity
Tracking and analyzing the buying and selling activities of Brian Hansen against Tandem Diabetes stock is an integral part of due diligence when investing in Tandem Diabetes. Brian Hansen insider activity provides valuable insight into whether Tandem Diabetes is net buyers or sellers over its current business cycle. Note, Tandem Diabetes insiders must abide by specific rules, including filing SEC forms every time they buy or sell Tandem Diabetes'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Brian Hansen over a week ago Acquisition by Brian Hansen of 50000 shares of Franklin Street at 5.6828 subject to Rule 16b-3 | ||
Brian Hansen over six months ago Acquisition by Brian Hansen of 2941 shares of Franklin Street at 2.745 subject to Rule 16b-3 | ||
Brian Hansen over six months ago Acquisition by Brian Hansen of 40903 shares of Franklin Street at 2.3815 subject to Rule 16b-3 | ||
Brian Hansen over six months ago Acquisition by Brian Hansen of 12019 shares of Franklin Street subject to Rule 16b-3 |
Tandem Diabetes Management Efficiency
The company has return on total asset (ROA) of (0.0645) % which means that it has lost $0.0645 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.333) %, meaning that it created substantial loss on money invested by shareholders. Tandem Diabetes' management efficiency ratios could be used to measure how well Tandem Diabetes manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Robert Hoedt | Medtronic PLC | 64 | |
| Brent Ladd | Stryker | N/A | |
| Richard Kuntz | Medtronic PLC | 63 | |
| Jodi Eddy | Boston Scientific Corp | 51 | |
| Bradley Lerman | Medtronic PLC | 63 | |
| Daniel Salvadori | Abbott Laboratories | 46 | |
| John Capek | Abbott Laboratories | 59 | |
| Eric Benjamin | Insulet | 42 | |
| Joseph Fitzgerald | Boston Scientific Corp | 61 | |
| David Pierce | Boston Scientific Corp | 57 | |
| Robert Funck | Abbott Laboratories | 63 | |
| Sandra Lesenfants | Penumbra | N/A | |
| Desiree RallsMorrison | Boston Scientific Corp | 54 | |
| Viju Menon | Stryker | 57 | |
| Jeffrey Mirviss | Boston Scientific Corp | 58 | |
| Edward Mackey | Boston Scientific Corp | 58 | |
| Karen Parkhill | Medtronic PLC | 59 | |
| Jaime Contreras | Abbott Laboratories | 62 | |
| Arthur Butcher | Boston Scientific Corp | 54 | |
| Dylan Crotty | Stryker | N/A | |
| Charles Alpuche | Insulet | 64 | |
Management Performance
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.0645 |
Tandem Diabetes Care Leadership Team
Elected by the shareholders, the Tandem Diabetes' board of directors comprises two types of representatives: Tandem Diabetes inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Tandem. The board's role is to monitor Tandem Diabetes' management team and ensure that shareholders' interests are well served. Tandem Diabetes' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Tandem Diabetes' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Brian Hansen, Chief Commercial Officer, Executive Vice President | ||
| Tom Fox, Chief Officer | ||
| Susan Morrison, Chief Admin. Officer | ||
| Mark Novara, Executive Officer | ||
| Ross Sylvia, VP Marketing | ||
| David Esq, Transitional Advisor | ||
| Jordan MD, Chief Officer | ||
| Libba Sapitsky, Senior Care | ||
| Shannon JD, Chief VP | ||
| JeanClaude Kyrillos, Executive COO | ||
| Leigh Vosseller, Senior Vice President - Finance | ||
| Rick Carpenter, Chief Officer | ||
| John Sheridan, COO and Executive VP | ||
| Elizabeth Gasser, Executive Officer | ||
| Shannon Hansen, Privacy Legal |
Tandem Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Tandem Diabetes a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.0645 | ||||
| Profit Margin | (0.10) % | ||||
| Operating Margin | (0) % | ||||
| Current Valuation | 1.41 B | ||||
| Shares Outstanding | 66.47 M | ||||
| Shares Owned By Insiders | 0.84 % | ||||
| Shares Owned By Institutions | 99.16 % | ||||
| Number Of Shares Shorted | 7.08 M | ||||
| Price To Earning | 494.25 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios, which includes a position in Tandem Diabetes Care. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.